Menu Search
Equities

Pacific Biosciences of California Inc

PACB:NSQ

Pacific Biosciences of California Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.77
  • Today's Change0.05 / 2.91%
  • Shares traded7.90k
  • 1 Year change-78.62%
  • Beta1.9576
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Pacific Biosciences of California Inc grew revenues 56.29% from 128.30m to 200.52m while net income improved from a loss of 314.25m to a smaller loss of 306.74m.
Gross margin23.81%
Net profit margin-227.69%
Operating margin-236.12%
Return on assets-23.55%
Return on equity-64.80%
Return on investment-25.40%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Pacific Biosciences of California Inc fell by 145.68m. Cash Flow from Financing totalled 108.89m or 54.30% of revenues. In addition the company used 259.17m for operations while cash from investing totalled 4.60m.
Cash flow per share-1.30
Price/Cash flow per share--
Book value per share1.65
Tangible book value per share-1.29
More ▼

Balance sheet in USDView more

Pacific Biosciences of California Inc has a Debt to Total Capital ratio of 66.34%, a lower figure than the previous year's 116.79%.
Current ratio9.74
Quick ratio8.64
Total debt/total equity1.97
Total debt/total capital0.6634
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.